ALEC
Alector, Inc.Healthcare · $252M market cap
Verdict
We can't put a fair value on ALEC right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
2 of 5 clear the 10% bar. What are the Big Five?
Follow ALEC
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 2, 2026: no open-market purchases and 5 sales worth $296K. Why purchases matter
Sales
Wong-Sarad Grace
Principal Accounting Officer · 2026-09-04
Sold
$9K
Rosenthal Arnon
Chief Executive Officer · 2026-09-03
Sold
$193K
Berkley Neil Lindsay
CFO & Chief Business Officer · 2026-09-03
Sold
$78K
Wong-Sarad Grace
Principal Accounting Officer · 2026-09-03
Sold
$14K
Wong-Sarad Grace
Principal Accounting Officer · 2026-09-02
Sold
$2K
About Alector, Inc.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works